Page last updated: 2024-11-12

bluensomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

bluensomycin: differs from dihydrostreptomycin only in absence of guanidino group; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID20055290
CHEMBL ID2104642
CHEBI ID81193
SCHEMBL ID691672
MeSH IDM0049533

Synonyms (25)

Synonym
u 12898
bluensin
d-scyllo-inositol, o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1=>2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1=>2)-1-((aminoiminomethyl)amino)-1-deoxy-, 5-carbamate
bluensomycin [inn]
antibiotic obtained from cultures of streptomyces verticillus, or the same substance produced by any other means
bluensomycine [inn-french]
u 12898d
u-12898
bluensomicina [inn-spanish]
bluensomycinum [inn-latin]
11011-72-6
bluensomycin
C17573
lwv7pwe57u ,
bluensomicina
bluensomycinum
bluensomycine
unii-lwv7pwe57u
CHEMBL2104642
chebi:81193 ,
SCHEMBL691672
Q27155138
gtpl10765
u12898
[(1r,2s,3s,4r,5r,6r)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl] carbamate

Research Excerpts

Overview

Bluensomycin (glebomycin) is an aminocyclitol antibiotic. It differs structurally from dihydrostreptomycin in having bluensidine (1D-1-O-carbamoyl-3-guanidinodeoxy-scyllo-inositol) rather than streptidine.

ExcerptReferenceRelevance
"Bluensomycin (glebomycin) is an aminocyclitol antibiotic that differs structurally from dihydrostreptomycin in having bluensidine (1D-1-O-carbamoyl-3-guanidinodeoxy-scyllo-inositol) rather than streptidine (1,3-diguanidino-1,3-dideoxy-scyllo-inositol) as its aminocyclitol moiety. "( Possible evolutionary relationships between streptomycin and bluensomycin biosynthetic pathways: detection of novel inositol kinase and O-carbamoyltransferase activities.
Walker, JB, 1990
)
1.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino sugarAny sugar having one or more alcoholic hydroxy groups replaced by substituted or unsubstituted amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's4 (57.14)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]